新风医疗集团近日从纽交所退市，股权价值约为 15.82 亿美元，成为市场上De-SPAC之后又退市的第一起案例。达维律师事务所、迈普达律师事务所为公司董事会特别委员会提供法律意见；环球律师事务所、盛信律师事务所、奥杰律师事务所则担任买方财团的法律顾问。

新风医疗集团在2019年通过De-SPAC交易将国内全国性综合医疗服务提供商和睦家医疗集团的业务在美国上市。此次退市是和睦家医疗集团的第二次私有化。早前和睦家医疗集团曾以美中互利为主体在美国纳斯达克挂牌交易，在2014年由复星医药和TPG牵头完成“私有化”交易退市。

达维团队由北京办公室首席代表、全球合伙人张新华律师牵头领导。

买方财团包括新风天域集团及其关联投资实体、维梧资本、复星医药、华平投资及其关联方、高盛资产管理的私募股权业务，以及其他若干投资者。

Davis Polk, STB and Ogier led on privatization of New Frontier Health

Davis Polk & Wardwell and Maples and Calder has advised the board of directors of New Frontier Health on the company’s privatization, with Simpson Thacher & Bartlett, Ogier and Global Law Office advising the buyer consortium. 

New Frontier Health is New Frontier Group’s first SPAC, which acquired United Family Healthcare, a healthcare services provider, in 2019, making the latter listed in New York. This is United Family Healthcare’s second privatization since the company’s de-listing from Nasdaq in 2014.

The David Polk’s team was led by partner Howard Zhang. 

The consortium included New Frontier Public Holding, HMJ Holdings, an NFPH-affiliated investment vehicle, Vivo Capital Fund IX (Cayman), Fosun Industrial, the Private Equity business within Goldman Sachs Asset Management, certain affiliate of Warburg Pincus LLC and certain other investors.

To contact the editorial team, please email ALBEditor@thomsonreuters.com.